LUCD — Lucid Diagnostics Inc. Common Stock
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Company profile
- Sector: Healthcare
- Industry: Medical - Devices
- Country: US
- Exchange: NASDAQ
- Employees: 82
- Website: https://www.luciddx.com
Latest SEC filings for LUCD
- 8-K — 2026-09-22
- 8-K — 2026-08-13
- 10-Q — 2026-08-12
- 8-K — 2026-06-24
- 8-K — 2026-05-14
- 10-Q — 2026-05-13
- ARS — 2026-04-30
- 8-K — 2026-04-24
- 8-K — 2026-04-23
- 424B5 — 2026-04-23
Latest LUCD news
- — Oil Above $100 Puts Penny Stocks in Focus (GlobeNewswire Inc.)
- — PAVmed subsidiary Lucid Diagnostics raises $15 million in preferred stock sale - Investing.com Nigeria (Investing.com Nigeria)
- — PAVmed subsidiary Lucid Diagnostics raises $15 million in preferred stock sale - Investing.com Canada (Investing.com Canada)
- — Lucid Diagnostics Raises $15 Million Through Series C Preferred Stock Offering - TradingView (TradingView)
- — Lucid Diagnostics raises $15 million through Series C preferred stock sale - Investing.com Nigeria (Investing.com Nigeria)
- — A 20% annual dividend comes with Lucid Diagnostics (LUCD)'s preferred stock sale. - Stock Titan (Stock Titan)
- — Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing - Morningstar (Morningstar)
Educational tool only — not investment advice.